Neurogene Stock (NASDAQ:NGNE)
Previous Close
$17.99
52W Range
$6.88 - $74.49
50D Avg
$13.97
200D Avg
$27.37
Market Cap
$260.21M
Avg Vol (3M)
$272.81K
Beta
1.56
Div Yield
-
NGNE Company Profile
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.